Delcath Announces First Patient Treated In ICC Cohort Of Global Phase 2 HCC Trial Program

[frothmouth]

“Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that the first treatment with the Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT